Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 25,660 | 18,592 | 39,648 | 27,142 | 47,480 |
| TOTAL | $27,710 | $20,552 | $41,820 | $29,465 | $48,209 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 490 | 733 | 7 | 135 | 258 |
| TOTAL | $490 | $733 | $7 | $135 | $258 |
| Total Assets | $28,200 | $21,285 | $41,827 | $29,600 | $48,467 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 6,431 | 3,890 | 1,805 | 1,292 | 1,661 |
| Accrued Expenses | 9,182 | 9,058 | 7,163 | 4,042 | 1,093 |
| TOTAL | $15,676 | $13,012 | $9,033 | $5,399 | $2,820 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 72,765 | 40,467 | 30,178 | 8 | 52 |
| TOTAL | $72,765 | $40,467 | $30,178 | $8 | $52 |
| Total Liabilities | $88,441 | $53,479 | $39,211 | $5,407 | $2,872 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 61,904 | 59,444 | 59,358 | 57,156 | 57,031 |
| Common Shares | 61 | 59 | 59 | 56 | 56 |
| Retained earnings | -354,372 | -309,567 | -270,694 | -239,996 | -216,394 |
| Other shareholders' equity | 2,223 | 2,233 | 2,250 | 2,250 | 2,260 |
| TOTAL | $-60,241 | $-32,194 | $2,616 | $24,193 | $45,595 |
| Total Liabilities And Equity | $28,200 | $21,285 | $41,827 | $29,600 | $48,467 |